BridgeBio Pharma Q3 revenue more than doubles on Attruby sales and Bayer milestone
BBIO•BridgeBio Pharma’s third-quarter revenue more than doubled year over year, driven by higher Attruby sales and a one-time $75 million Bayer milestone. The company reported a $60.50 million net loss and a $0.42 loss per share.
1. Sales and milestone
BridgeBio Pharma said higher U.S. Attruby net product sales and a one-time $75 million sales milestone from Bayer under a license agreement primarily drove its third-quarter revenue increase. Attruby growth was led by treatment-naïve patients and a higher share of new patient starts.
2. Costs and outlook
The company posted an operating loss as selling, general and administrative expenses and research and development spending rose with commercialization and late-stage development investments. BridgeBio expects U.S. launches of BBP-418, oral infigratinib and encaleret upon FDA approval; the stated FDA decision or action dates are November 2026, February 2027 and May 2027, respectively.
